Overall survival · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with chemoradiotherapy showed no clear difference in overall survival Median compared with internal radiotherapy (brachytherapy) with chemoradiotherapy (low certainty).
1 finding from 1 review
Progression or event‐free survival Median · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with chemoradiotherapy showed no clear difference in progression or event‐free survival Median compared with internal radiotherapy (brachytherapy) with chemoradiotherapy (low certainty).
1 finding from 1 review
Quality of life · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe late complications · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with chemoradiotherapy may leads to higher severe late complications compared with internal radiotherapy (brachytherapy) with chemoradiotherapy (low certainty).
1 finding from 1 review
Intervention not reported
3‐year overall survival rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year overall survival rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
Locaregional recurrence · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in locaregional recurrence (moderate certainty).
1 finding from 1 review
Intervention not reported
Distant metastasis · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in distant metastasis (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year overall survival rate (3 to 6 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year overall survival rate (3 to 6 yr) (low certainty).
1 finding from 1 review
Intervention not reported
10‐year overall survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year overall survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
10‐year disease specific survival rate (5 to 15 yr) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 10‐year disease specific survival rate (5 to 15 yr) (moderate certainty).
1 finding from 1 review
Intervention not reported
3‐year relapse‐free survive rate (37.2/40.2 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 3‐year relapse‐free survive rate (37.2/40.2 mo) (low certainty).
1 finding from 1 review
Intervention not reported
5‐year relapse‐free survive rate (66 mo) · women with locally advanced uterine cervix cancer
The intervention showed no clear difference in 5‐year relapse‐free survive rate (66 mo) (low certainty).
1 finding from 1 review